IP Library Granted Patent US 11,376,275
Granted Patent B2
US 11,376,275 · App. 17/060,343 · Granted Jul 5, 2022

Ophthalmic compositions with improved dessication protection and retention

Inventors: James W. Davis (Falmouth, ME); Howard Allen Ketelson (Dallas, TX); Elaine E. Campbell (Shelton, CT); David L. Meadows (Colleyville, TX); Rekha Rangarajan (Fort Worth, TX)
Assignee: Alcon Inc.
A61K31/736A61K9/0048A61K31/728A61K47/02A61K47/10A61K47/26A61K47/32A61K47/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,376,275
App. No.
17/060,343
Granted
Jul 5, 2022
Kind
B2
Abstract

The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the to compositions also comprise a borate compound.

Claims (8)

1. An ophthalmic composition comprising 0.1 to 0.2 w/v % hydroxylpropyl guar, 0.13 to 0.17 w/v % hyaluronic acid, and 1.0 to 2.0 w/v % cis-diol, wherein said cis-diol is sorbitol.

2. The ophthalmic composition according to claim 1 comprising 0.17 to 0.18 w/v % hydroxylpropyl guar, 0.13 to 0.17 w/v % sodium hyaluronate, and 1.4 w/v % sorbitol.

3. The ophthalmic composition according to claim 1 further comprising a borate, wherein said borate is boric acid.

4. The ophthalmic composition according to claim 1 further comprising a demulcent selected from the group consisting of: glycerin, polyvinyl pyrrolidone, polyethylene oxide, polyethylene glycol, propylene glycol, polyacrylic acid, and combinations thereof.

5. The ophthalmic composition according to claim 4 , wherein said demulcent is polypropylene glycol or polyethylene glycol.

6. The ophthalmic composition according to claim 1 further comprising a pharmaceutically active compound.

7. The ophthalmic composition according to claim 1 , for use in treating ophthalmic disease.

8. The ophthalmic composition for use according to claim 7 , wherein the ophthalmic disease is dry eye.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2020
From: DAVIS, JAMES W.; KETELSON, HOWARD ALLEN; CAMPBELL, ELAINE E.; MEADOWS, DAVID L.; RANGARAJAN, REKHA
To: ALCON RESEARCH, LTD.
Reel/Frame 054258/0053 →
MERGER Recorded Nov 3, 2020
From: ALCON RESEARCH, LTD.
To: ALCON RESEARCH, LLC
Reel/Frame 054258/0167 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2020
From: ALCON RESEARCH, LLC
To: ALCON INC.
Reel/Frame 054258/0263 →